About: Jonathan M. Brotchie

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Jonathan M. Brotchie Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) researcher (en) 연구원 (ko) ricercatore (it) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy)
rdfs:label	Jonathan M. Brotchie (en) Jonathan M. Brotchie (es) Jonathan M. Brotchie (nl) Jonathan M. Brotchie (sl) Jonathan M. Brotchie (ast)
skos:prefLabel	Jonathan M. Brotchie (en) Jonathan M. Brotchie (es) Jonathan M. Brotchie (nl) Jonathan M. Brotchie (sl) Jonathan M. Brotchie (ast)
name	Jonathan M. Brotchie (en) Jonathan M. Brotchie (es) Jonathan M. Brotchie (nl) Jonathan M. Brotchie (sl) Jonathan M. Brotchie (ast)
Scopus author ID	wds:Q55079469-3D6AB78D-C417-4793-8D71-5F85AFE8B54D
Scopus author ID	7006764019
given name	wds:Q55079469-2DF874CF-FAFF-47C4-A9E7-9B783C64361C
given name	Jonathan
instance of	wds:Q55079469-05F0798E-D0E1-4EE7-AD00-8F503A692458
instance of	Homo sapiens
Academic Tree ID	wds:Q55079469-793EEE47-38FF-4A38-B1FD-0E8784519585
Academic Tree ID	15802
Semantic Scholar author ID	wds:Q55079469-3435106A-335C-455F-98B8-21D8060ACC8F
Semantic Scholar author ID	4889485
skos:altLabel	J M Brotchie (en) JM Brotchie (en) Jonathan Brotchie (en)
occupation	wds:Q55079469-3B11CDCB-CD7F-4606-B2ED-F65166B947A2
sex or gender	wds:Q55079469-C89F4DA9-F107-4743-9560-379F09800C85
VIAF ID	wds:Q55079469-6DD20E72-10E9-4FDF-A3DA-69BA9377D49E
Library of Congress authority ID	wds:Q55079469-DB5F3C65-F342-47D8-B112-3675FF1CCEF7
IdRef ID	wds:Q55079469-a767dbf7-2f37-4762-82c8-22f8bed256d0
educated at	wds:Q55079469-2302C4C5-BD25-406D-B65F-34A970119296 wds:Q55079469-7454AD41-8D5A-4FB4-A683-104D786C5789 wds:Q55079469-A7C5B1C9-18BC-404D-949F-6F5267C1BE91
WorldCat Identities ID (superseded)	wds:Q55079469-DF7BE547-BB19-4E21-A6EE-52BDCDB9CAA3
VIAF ID	http://viaf.org/viaf/192625995
Library of Congress authority ID	http://id.loc.gov/authorities/names/ns2011001620
IdRef ID	http://www.idref.fr/189316535/id
occupation	researcher
sex or gender	male
VIAF ID	192625995
Library of Congress authority ID	ns2011001620
IdRef ID	189316535
educated at	University of Manchester
WorldCat Identities ID (superseded)	lccn-ns2011001620
ORCID iD	wds:Q55079469-54BD0D9E-C948-4D5B-A231-CB0E752E7166
ORCID iD	https://orcid.org/0000-0003-2337-0816
ORCID iD	0000-0003-2337-0816
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q55079469
is author of	Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus Levodopa-induced dyskinesias Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat Presymptomatic compensation in Parkinson's disease is not dopamine-mediated Mechanisms compensating for dopamine loss in early Parkinson disease Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy Levodopa-induced dyskinesia in Parkinson's disease. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice Serotonin and Parkinson's disease: On movement, mood, and madness Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease Advances in the delivery of treatments for Parkinson's disease Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Novel pharmacological targets for the treatment of Parkinson's disease Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. The serotonergic system in Parkinson's disease A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software